Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal

Investigators Highlight Promising T-Cell Response

Oxford’s long-awaited early stage study produces solid safety and efficacy results, but lags Pfizer/BioNTech and Moderna’s mRNA candidates for antibody response.

Old Road Campus
Oxford is racing ahead in its Phase III trials, having dosed nearly all its target of 10,000 volunteers.

The University of Oxford and AstraZeneca PLC have released Phase I results from their COVID-19 vaccine, the early trial producing encouraging safety and efficacy signals, but a neutralizing antibody response that appears to be less strong than its rivals.

The study published in The Lancet of more than 1,000 healthy adult volunteers provides a solid base for the partners...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip